JP2022530533A - Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 - Google Patents

Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 Download PDF

Info

Publication number
JP2022530533A
JP2022530533A JP2021564454A JP2021564454A JP2022530533A JP 2022530533 A JP2022530533 A JP 2022530533A JP 2021564454 A JP2021564454 A JP 2021564454A JP 2021564454 A JP2021564454 A JP 2021564454A JP 2022530533 A JP2022530533 A JP 2022530533A
Authority
JP
Japan
Prior art keywords
antibody
asthma
dose
antigen
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564454A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020223541A5 (https=
JP2022530533A5 (https=
Inventor
ヘレーネ・グーラウィック
アンドレアス・ジェッセル
ラオラット・アブデュライ
アリエール・テパー
アレックス・ボディ
チー－チ・フー
デボラ・デュコヴィッチ
マルセラ・ルディ
ニキル・アミン
シヴァン・ハレル
ジョージオス・カリオリアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022530533A publication Critical patent/JP2022530533A/ja
Publication of JPWO2020223541A5 publication Critical patent/JPWO2020223541A5/ja
Publication of JP2022530533A5 publication Critical patent/JP2022530533A5/ja
Priority to JP2025080870A priority Critical patent/JP2025122028A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021564454A 2019-05-01 2020-04-30 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 Pending JP2022530533A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080870A JP2025122028A (ja) 2019-05-01 2025-05-14 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962841481P 2019-05-01 2019-05-01
US62/841,481 2019-05-01
US201962848248P 2019-05-15 2019-05-15
US62/848,248 2019-05-15
US201962898900P 2019-09-11 2019-09-11
US62/898,900 2019-09-11
PCT/US2020/030824 WO2020223541A1 (en) 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080870A Division JP2025122028A (ja) 2019-05-01 2025-05-14 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Publications (3)

Publication Number Publication Date
JP2022530533A true JP2022530533A (ja) 2022-06-29
JPWO2020223541A5 JPWO2020223541A5 (https=) 2024-09-13
JP2022530533A5 JP2022530533A5 (https=) 2024-09-13

Family

ID=70802932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564454A Pending JP2022530533A (ja) 2019-05-01 2020-04-30 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2025080870A Pending JP2025122028A (ja) 2019-05-01 2025-05-14 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080870A Pending JP2025122028A (ja) 2019-05-01 2025-05-14 Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Country Status (15)

Country Link
US (1) US20210000949A1 (https=)
EP (1) EP3962515A1 (https=)
JP (2) JP2022530533A (https=)
KR (1) KR20220004708A (https=)
CN (1) CN113766931A (https=)
AU (1) AU2020266593B2 (https=)
BR (1) BR112021021195A2 (https=)
CA (1) CA3138306A1 (https=)
CO (1) CO2021015793A2 (https=)
IL (1) IL287275A (https=)
MA (1) MA55807A (https=)
MX (1) MX2021013427A (https=)
SG (1) SG11202111255YA (https=)
TW (1) TWI894144B (https=)
WO (1) WO2020223541A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
AU2022335719B2 (en) 2021-08-27 2024-11-28 Medimmune Limited Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
MX2024005769A (es) * 2021-11-11 2024-05-24 Regeneron Pharma Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33).
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
JP6306588B2 (ja) * 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
ES3052989T3 (en) * 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
SG11201909048TA (en) * 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HISTORY OF CHANGES FOR STUDY: NCT03387852, CLINICALTRIALS.GOV ARCHIVE, [ONLINE], JPN6024020985, 19 April 2019 (2019-04-19), ISSN: 0005676027 *
LIU, X. ET AL.: "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 386, no. 1, JPN6024020987, 2009, pages 181 - 185, ISSN: 0005676029 *
MCGREGOR, M. C. ET AL.: "Role of Biologics in Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 199, no. 4, JPN6024020986, 15 February 2019 (2019-02-15), pages 433 - 445, ISSN: 0005676028 *
出原 賢治: "気管支喘息の病態に関する基礎研究のカッティングエッジに迫る", RESPIRATORY MEDICAL RESEARCH, vol. 第1巻，第1号, JPN6025036606, 2013, pages 14 - 18, ISSN: 0005676030 *

Also Published As

Publication number Publication date
MA55807A (fr) 2022-03-09
JP2025122028A (ja) 2025-08-20
AU2020266593B2 (en) 2026-02-12
TWI894144B (zh) 2025-08-21
IL287275A (en) 2021-12-01
EP3962515A1 (en) 2022-03-09
BR112021021195A2 (pt) 2022-03-03
CO2021015793A2 (es) 2021-11-30
KR20220004708A (ko) 2022-01-11
AU2020266593A1 (en) 2021-11-11
CA3138306A1 (en) 2020-11-05
CN113766931A (zh) 2021-12-07
MX2021013427A (es) 2022-01-31
US20210000949A1 (en) 2021-01-07
SG11202111255YA (en) 2021-11-29
WO2020223541A1 (en) 2020-11-05
TW202106334A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP7315545B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP6673840B2 (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
TWI757893B (zh) Il-4r拮抗劑用於製造治療鼻息肉症的藥物之用途
JP2022530533A (ja) Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
TW202502819A (zh) 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
JP2023505215A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
RU2793745C2 (ru) Способы лечения или предупреждения астмы путем введения антагониста il-4r
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
KR20260048354A (ko) Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250514